ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 214 filers reported holding ACADIA PHARMACEUTICALS INC in Q1 2016. The put-call ratio across all filers is 0.96 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2016 | $11,833,000 | +9366.4% | 372 | -90.3% | 0.02% | -83.3% |
| Q2 2016 | $125,000 | -99.9% | 3,836 | -34.1% | 0.10% | -1.0% |
| Q1 2016 | $162,755,000 | +164299.0% | 5,821 | +110.1% | 0.10% | +71.7% |
| Q4 2015 | $99,000 | -43.1% | 2,771 | -47.2% | 0.06% | -50.8% |
| Q3 2015 | $174,000 | -42.2% | 5,251 | -27.0% | 0.12% | -32.6% |
| Q2 2015 | $301,000 | +25.4% | 7,195 | -2.2% | 0.18% | +34.1% |
| Q1 2015 | $240,000 | -81.1% | 7,360 | -81.6% | 0.14% | -76.7% |
| Q4 2014 | $1,268,000 | +18.6% | 39,950 | -7.5% | 0.58% | +15.3% |
| Q3 2014 | $1,069,000 | +8.3% | 43,180 | -1.2% | 0.50% | +10.3% |
| Q2 2014 | $987,000 | +78.8% | 43,710 | +92.8% | 0.46% | +61.3% |
| Q1 2014 | $552,000 | -2.6% | 22,670 | 0.0% | 0.28% | -2.4% |
| Q4 2013 | $567,000 | -39.1% | 22,670 | -33.1% | 0.29% | -40.5% |
| Q3 2013 | $931,000 | – | 33,893 | – | 0.49% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 556,553 | $11,598,565 | 5.78% |
| Baker Brothers Advisors | 42,864,612 | $893,298,514 | 5.15% |
| RTW INVESTMENTS, LP | 11,576,537 | $241,255,031 | 5.09% |
| Palo Alto Investors LP | 2,405,793 | $50,136,726 | 4.74% |
| Birchview Capital, LP | 240,400 | $5,009,936 | 4.26% |
| EcoR1 Capital, LLC | 5,991,479 | $124,862,422 | 4.21% |
| EMERALD ADVISERS, LLC | 1,681,052 | $35,033,124 | 1.70% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 1,303,988 | $27,175,110 | 1.64% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 179,702 | $3,739,599 | 1.26% |
| SECTOR GAMMA AS | 179,785 | $3,746,719 | 0.96% |